 John Hamner
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 8 | 2009 | 133 | 0.900 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2017 | 858 | 0.840 |
Why?
| | Interferon-beta | 7 | 2010 | 79 | 0.670 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2019 | 3 | 0.660 |
Why?
| | Gastric Outlet Obstruction | 1 | 2019 | 7 | 0.660 |
Why?
| | Duodenal Neoplasms | 1 | 2019 | 19 | 0.650 |
Why?
| | Carcinoma, Lobular | 1 | 2019 | 44 | 0.630 |
Why?
| | Urologic Neoplasms | 1 | 2017 | 25 | 0.560 |
Why?
| | Hepatectomy | 1 | 2017 | 119 | 0.540 |
Why?
| | Pancreaticoduodenectomy | 1 | 2015 | 133 | 0.470 |
Why?
| | Neoplasms, Second Primary | 1 | 2015 | 92 | 0.460 |
Why?
| | Liver Neoplasms | 1 | 2017 | 506 | 0.430 |
Why?
| | Neovascularization, Pathologic | 5 | 2010 | 281 | 0.420 |
Why?
| | Breast Neoplasms | 2 | 2019 | 1862 | 0.420 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2015 | 211 | 0.420 |
Why?
| | Adenocarcinoma | 2 | 2015 | 795 | 0.400 |
Why?
| | Genetic Therapy | 3 | 2008 | 257 | 0.340 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2010 | 698 | 0.330 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 731 | 0.310 |
Why?
| | Hydroxamic Acids | 1 | 2008 | 80 | 0.290 |
Why?
| | Melanoma | 3 | 2018 | 620 | 0.290 |
Why?
| | Boronic Acids | 1 | 2007 | 33 | 0.290 |
Why?
| | Lymphedema | 1 | 2007 | 20 | 0.280 |
Why?
| | Pyrazines | 1 | 2007 | 71 | 0.280 |
Why?
| | Soft Tissue Neoplasms | 1 | 2007 | 90 | 0.270 |
Why?
| | Skin Neoplasms | 3 | 2018 | 756 | 0.270 |
Why?
| | Mice, SCID | 9 | 2010 | 314 | 0.260 |
Why?
| | Pain, Postoperative | 1 | 2007 | 191 | 0.250 |
Why?
| | Antineoplastic Agents | 5 | 2007 | 1879 | 0.240 |
Why?
| | Combined Modality Therapy | 3 | 2015 | 1121 | 0.220 |
Why?
| | Head and Neck Neoplasms | 2 | 2018 | 427 | 0.220 |
Why?
| | Aged | 8 | 2019 | 19074 | 0.180 |
Why?
| | Stem Cells | 3 | 2009 | 546 | 0.170 |
Why?
| | Radiation Tolerance | 2 | 2010 | 92 | 0.160 |
Why?
| | Cell Line, Tumor | 8 | 2010 | 2710 | 0.160 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1167 | 0.160 |
Why?
| | Disease-Free Survival | 2 | 2017 | 620 | 0.160 |
Why?
| | Tumor Burden | 4 | 2018 | 259 | 0.150 |
Why?
| | In Vitro Techniques | 3 | 2009 | 1016 | 0.140 |
Why?
| | Angiogenesis Inhibitors | 2 | 2010 | 214 | 0.140 |
Why?
| | Postoperative Complications | 1 | 2007 | 2128 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2017 | 4411 | 0.130 |
Why?
| | Erlotinib Hydrochloride | 1 | 2015 | 64 | 0.130 |
Why?
| | Bone Neoplasms | 2 | 2009 | 194 | 0.130 |
Why?
| | Adenoviridae | 4 | 2008 | 184 | 0.120 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2015 | 43 | 0.120 |
Why?
| | Thyroid Neoplasms | 1 | 2018 | 264 | 0.120 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2015 | 59 | 0.120 |
Why?
| | Deoxycytidine | 1 | 2015 | 138 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2017 | 419 | 0.120 |
Why?
| | Stomach Neoplasms | 1 | 2014 | 65 | 0.120 |
Why?
| | Immunotherapy | 1 | 2018 | 474 | 0.110 |
Why?
| | Prognosis | 3 | 2018 | 3329 | 0.110 |
Why?
| | Female | 9 | 2019 | 59507 | 0.110 |
Why?
| | Humans | 19 | 2019 | 114686 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2018 | 480 | 0.100 |
Why?
| | Mice | 11 | 2010 | 14869 | 0.100 |
Why?
| | Health Status Disparities | 1 | 2014 | 200 | 0.100 |
Why?
| | Retrospective Studies | 5 | 2018 | 12550 | 0.100 |
Why?
| | Middle Aged | 7 | 2018 | 26737 | 0.100 |
Why?
| | Male | 13 | 2018 | 55596 | 0.100 |
Why?
| | Oxygen Consumption | 2 | 2010 | 588 | 0.090 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2010 | 10 | 0.090 |
Why?
| | Osteoprotegerin | 1 | 2009 | 23 | 0.080 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2008 | 68 | 0.080 |
Why?
| | Cyclophosphamide | 1 | 2008 | 217 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1355 | 0.070 |
Why?
| | Subcutaneous Tissue | 1 | 2007 | 17 | 0.070 |
Why?
| | Bortezomib | 1 | 2007 | 41 | 0.070 |
Why?
| | Animals | 11 | 2010 | 31706 | 0.070 |
Why?
| | Stockings, Compression | 1 | 2007 | 5 | 0.070 |
Why?
| | Skin Care | 1 | 2007 | 18 | 0.070 |
Why?
| | Topotecan | 1 | 2007 | 10 | 0.070 |
Why?
| | Random Allocation | 1 | 2008 | 335 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2018 | 9088 | 0.070 |
Why?
| | Probability | 1 | 2008 | 289 | 0.070 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 523 | 0.070 |
Why?
| | Glioma | 1 | 2010 | 294 | 0.070 |
Why?
| | Neoplasm Transplantation | 4 | 2007 | 228 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2008 | 3535 | 0.070 |
Why?
| | Drainage | 1 | 2007 | 151 | 0.070 |
Why?
| | Diphosphonates | 1 | 2006 | 51 | 0.070 |
Why?
| | Bone Density Conservation Agents | 1 | 2006 | 62 | 0.060 |
Why?
| | Clinical Protocols | 1 | 2007 | 233 | 0.060 |
Why?
| | Analgesics | 1 | 2007 | 158 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2010 | 2187 | 0.060 |
Why?
| | Imidazoles | 1 | 2006 | 208 | 0.060 |
Why?
| | Blood Vessels | 1 | 2007 | 180 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1147 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2018 | 1075 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 2010 | 1262 | 0.060 |
Why?
| | Pain Measurement | 1 | 2007 | 444 | 0.060 |
Why?
| | Risk Factors | 1 | 2017 | 8632 | 0.060 |
Why?
| | United States | 5 | 2018 | 12183 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1692 | 0.050 |
Why?
| | Exercise Therapy | 1 | 2007 | 352 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2008 | 645 | 0.050 |
Why?
| | Genetic Vectors | 3 | 2008 | 289 | 0.050 |
Why?
| | Adult | 5 | 2018 | 30550 | 0.050 |
Why?
| | Chronic Disease | 1 | 2007 | 1578 | 0.050 |
Why?
| | Neurons | 1 | 2008 | 1280 | 0.040 |
Why?
| | Bevacizumab | 2 | 2010 | 115 | 0.040 |
Why?
| | Transduction, Genetic | 2 | 2009 | 113 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2018 | 275 | 0.040 |
Why?
| | Injections, Intravenous | 2 | 2008 | 198 | 0.040 |
Why?
| | California | 1 | 2018 | 353 | 0.030 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2017 | 99 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2017 | 139 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2007 | 6347 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 811 | 0.030 |
Why?
| | Drug Delivery Systems | 2 | 2008 | 296 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2010 | 663 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1078 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 196 | 0.030 |
Why?
| | Neoplasms | 1 | 2007 | 2097 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1125 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 1448 | 0.030 |
Why?
| | Sex Factors | 1 | 2018 | 1715 | 0.030 |
Why?
| | Young Adult | 2 | 2018 | 10469 | 0.020 |
Why?
| | Disease Progression | 2 | 2009 | 2380 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 2894 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1644 | 0.020 |
Why?
| | Registries | 1 | 2018 | 1768 | 0.020 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2010 | 38 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2010 | 72 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2010 | 181 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2010 | 221 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2313 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 4895 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 4409 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 385 | 0.020 |
Why?
| | Angiopoietin-1 | 1 | 2007 | 10 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 371 | 0.020 |
Why?
| | Dependovirus | 1 | 2007 | 52 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 135 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1230 | 0.020 |
Why?
| | Pressure | 1 | 2007 | 214 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 498 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 6115 | 0.010 |
Why?
| | Cell Movement | 1 | 2007 | 869 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 1842 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2637 | 0.010 |
Why?
| | Hypoxia | 1 | 2007 | 958 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 3886 | 0.010 |
Why?
| | Cytokines | 1 | 2007 | 1841 | 0.010 |
Why?
| | Phenotype | 1 | 2007 | 2796 | 0.010 |
Why?
| | Apoptosis | 1 | 2006 | 2363 | 0.010 |
Why?
|
|
Hamner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|